Key clinical point: Phase 2 trials of rheumatoid arthritis drugs often overestimate drug efficacy.
Major finding: The ACR20 response in phase 2 RA trials averaged 39% higher than in paired, subsequent phase 3 trials.
Study details: Analysis of 44 pairs of published phase 2 and 3 trials conducted in rheumatoid arthritis patients.
Disclosures: Dr. Kerschbaumer has been a speaker on behalf of Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, and Pfizer.
Kerschbaumer A et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):191-2. Abstract OP0229, doi: 10.1136/annrheumdis-2019-eular.5161.